Cite
HARVARD Citation
Rodríguez, P. et al. (n.d.). The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial. Clinical and experimental immunology. pp. 229-239. [Online].